Literature DB >> 30912890

Re: Prognosis of prostate cancer and prostate - specific antigen levels.

Beuy Joob1, Viroj Wiwanitkit2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30912890      PMCID: PMC6786117          DOI: 10.1590/S1677-5538.IBJU.2018.0867

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   1.541


× No keyword cloud information.
To the editor, We read the publication on “Prognosis of patients with prostate cancer and middle range prostate - specific antigen (PSA) levels of 20 – 100 ng / mL” with a great interest (1). Iwamoto et al. noted that “PSA is a useful biomarker for predicting prognosis at levels between 20 and 70 ng / mL (1)” and “When the PSA level reaches approximately 70 ng / mL, prognosis might bottom and reach a plateau (1)”. We would like to share ideas on this report. We agree that there might be a plateau phenomenon in case of high PSA level. Nevertheless, we should also be aware on the possible false negative result in patients with low PSA level (2). As an immunological test, the prozone effect is possible and this might lead to aberrant low PSA level (3). In that case, the prognosing might be affected.
  3 in total

1.  Advanced prostate cancer with extremely low prostate-specific antigen value at diagnosis: an example of high dose hook effect.

Authors:  Shusuke Akamatsu; Hideki Tsukazaki; Kouji Inoue; Yasunori Nishio
Journal:  Int J Urol       Date:  2006-07       Impact factor: 3.369

Review 2.  Determination of tumor markers in serum. Pitfalls and good practice.

Authors:  J P Basuyau; M Leroy; P Brunelle
Journal:  Clin Chem Lab Med       Date:  2001-12       Impact factor: 3.694

3.  Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 - 100 ng / mL.

Authors:  Hiroaki Iwamoto; Kouji Izumi; Yoshifumi Kadono; Atsushi Mizokami
Journal:  Int Braz J Urol       Date:  2019 Jan-Feb       Impact factor: 1.541

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.